International Assets Investment Management LLC decreased its position in electroCore, Inc. (NASDAQ:ECOR - Free Report) by 90.0% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 53,370 shares of the company's stock after selling 481,776 shares during the period. International Assets Investment Management LLC owned approximately 0.81% of electroCore worth $895,000 at the end of the most recent quarter.
Other large investors have also made changes to their positions in the company. Renaissance Technologies LLC increased its position in shares of electroCore by 3.4% during the second quarter. Renaissance Technologies LLC now owns 68,786 shares of the company's stock worth $442,000 after acquiring an additional 2,270 shares in the last quarter. Geode Capital Management LLC boosted its stake in electroCore by 10.3% in the 3rd quarter. Geode Capital Management LLC now owns 63,485 shares of the company's stock worth $458,000 after purchasing an additional 5,951 shares during the period. Finally, HighTower Advisors LLC bought a new position in electroCore during the 3rd quarter worth about $255,000. Institutional investors own 26.74% of the company's stock.
electroCore Price Performance
Shares of ECOR traded down $0.36 during mid-day trading on Friday, hitting $16.54. 83,548 shares of the company's stock were exchanged, compared to its average volume of 98,321. electroCore, Inc. has a 52 week low of $5.32 and a 52 week high of $18.67. The company has a market cap of $108.34 million, a PE ratio of -9.04 and a beta of 0.57. The company has a 50-day simple moving average of $13.66 and a 200 day simple moving average of $9.20.
Analysts Set New Price Targets
Separately, HC Wainwright boosted their price target on electroCore from $22.00 to $25.00 and gave the company a "buy" rating in a report on Wednesday, December 18th.
Check Out Our Latest Stock Analysis on ECOR
electroCore Company Profile
(
Free Report)
electroCore, Inc, a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania.
See Also
Before you consider electroCore, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and electroCore wasn't on the list.
While electroCore currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
